Cargando…
Application of Purified Botulinum Type A Neurotoxin to Treat Experimental Trigeminal Neuropathy in Rats and Patients with Urinary Incontinence and Prostatic Hyperplasia
Type A neurotoxin (NTX) of Clostridium botulinum was purified by a simple procedure using a lactose gel column. The toxicity of this purified toxin preparation was retained for at least 1 year at −30°C by supplementation with either 0.1% albumin or 0.05% albumin plus 1% trehalose. When purified NTX...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382382/ https://www.ncbi.nlm.nih.gov/pubmed/22745637 http://dx.doi.org/10.1155/2012/648384 |
_version_ | 1782236490090151936 |
---|---|
author | Matsuka, Yoshizo Yokoyama, Teruhiko Yamamoto, Yumiko Suzuki, Tomonori Dwi Fatmawati, Ni Nengah Nishikawa, Atsushi Ohyama, Tohru Watanabe, Toshihiro Kuboki, Takuo Nagai, Atsushi Oguma, Keiji |
author_facet | Matsuka, Yoshizo Yokoyama, Teruhiko Yamamoto, Yumiko Suzuki, Tomonori Dwi Fatmawati, Ni Nengah Nishikawa, Atsushi Ohyama, Tohru Watanabe, Toshihiro Kuboki, Takuo Nagai, Atsushi Oguma, Keiji |
author_sort | Matsuka, Yoshizo |
collection | PubMed |
description | Type A neurotoxin (NTX) of Clostridium botulinum was purified by a simple procedure using a lactose gel column. The toxicity of this purified toxin preparation was retained for at least 1 year at −30°C by supplementation with either 0.1% albumin or 0.05% albumin plus 1% trehalose. When purified NTX was used to treat 49 patients with urinary incontinence caused by either refractory idiopathic or neurogenic detrusor overactivity, 36 patients showed significant improvement in symptoms. These beneficial effects were also observed in cases of prostatic hyperplasia. The results obtained with NTX were similar to that of Botox. The effects of NTX on trigeminal neuralgia induced by infraorbital nerve constriction (IoNC) in rats were also studied. Trigeminal ganglion neurons from ipsilateral to IoNC exhibited significantly faster onset of FM4-64 release than sham-operated contralateral neurons. Intradermal injection of NTX in the area of IoNC alleviated IoNC-induced pain behavior and reduced the exaggerated FM4-64 release in trigeminal ganglion neurons. |
format | Online Article Text |
id | pubmed-3382382 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-33823822012-06-28 Application of Purified Botulinum Type A Neurotoxin to Treat Experimental Trigeminal Neuropathy in Rats and Patients with Urinary Incontinence and Prostatic Hyperplasia Matsuka, Yoshizo Yokoyama, Teruhiko Yamamoto, Yumiko Suzuki, Tomonori Dwi Fatmawati, Ni Nengah Nishikawa, Atsushi Ohyama, Tohru Watanabe, Toshihiro Kuboki, Takuo Nagai, Atsushi Oguma, Keiji J Toxicol Clinical Study Type A neurotoxin (NTX) of Clostridium botulinum was purified by a simple procedure using a lactose gel column. The toxicity of this purified toxin preparation was retained for at least 1 year at −30°C by supplementation with either 0.1% albumin or 0.05% albumin plus 1% trehalose. When purified NTX was used to treat 49 patients with urinary incontinence caused by either refractory idiopathic or neurogenic detrusor overactivity, 36 patients showed significant improvement in symptoms. These beneficial effects were also observed in cases of prostatic hyperplasia. The results obtained with NTX were similar to that of Botox. The effects of NTX on trigeminal neuralgia induced by infraorbital nerve constriction (IoNC) in rats were also studied. Trigeminal ganglion neurons from ipsilateral to IoNC exhibited significantly faster onset of FM4-64 release than sham-operated contralateral neurons. Intradermal injection of NTX in the area of IoNC alleviated IoNC-induced pain behavior and reduced the exaggerated FM4-64 release in trigeminal ganglion neurons. Hindawi Publishing Corporation 2012 2012-06-14 /pmc/articles/PMC3382382/ /pubmed/22745637 http://dx.doi.org/10.1155/2012/648384 Text en Copyright © 2012 Yoshizo Matsuka et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Matsuka, Yoshizo Yokoyama, Teruhiko Yamamoto, Yumiko Suzuki, Tomonori Dwi Fatmawati, Ni Nengah Nishikawa, Atsushi Ohyama, Tohru Watanabe, Toshihiro Kuboki, Takuo Nagai, Atsushi Oguma, Keiji Application of Purified Botulinum Type A Neurotoxin to Treat Experimental Trigeminal Neuropathy in Rats and Patients with Urinary Incontinence and Prostatic Hyperplasia |
title | Application of Purified Botulinum Type A Neurotoxin to Treat Experimental Trigeminal Neuropathy in Rats and Patients with Urinary Incontinence and Prostatic Hyperplasia |
title_full | Application of Purified Botulinum Type A Neurotoxin to Treat Experimental Trigeminal Neuropathy in Rats and Patients with Urinary Incontinence and Prostatic Hyperplasia |
title_fullStr | Application of Purified Botulinum Type A Neurotoxin to Treat Experimental Trigeminal Neuropathy in Rats and Patients with Urinary Incontinence and Prostatic Hyperplasia |
title_full_unstemmed | Application of Purified Botulinum Type A Neurotoxin to Treat Experimental Trigeminal Neuropathy in Rats and Patients with Urinary Incontinence and Prostatic Hyperplasia |
title_short | Application of Purified Botulinum Type A Neurotoxin to Treat Experimental Trigeminal Neuropathy in Rats and Patients with Urinary Incontinence and Prostatic Hyperplasia |
title_sort | application of purified botulinum type a neurotoxin to treat experimental trigeminal neuropathy in rats and patients with urinary incontinence and prostatic hyperplasia |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382382/ https://www.ncbi.nlm.nih.gov/pubmed/22745637 http://dx.doi.org/10.1155/2012/648384 |
work_keys_str_mv | AT matsukayoshizo applicationofpurifiedbotulinumtypeaneurotoxintotreatexperimentaltrigeminalneuropathyinratsandpatientswithurinaryincontinenceandprostatichyperplasia AT yokoyamateruhiko applicationofpurifiedbotulinumtypeaneurotoxintotreatexperimentaltrigeminalneuropathyinratsandpatientswithurinaryincontinenceandprostatichyperplasia AT yamamotoyumiko applicationofpurifiedbotulinumtypeaneurotoxintotreatexperimentaltrigeminalneuropathyinratsandpatientswithurinaryincontinenceandprostatichyperplasia AT suzukitomonori applicationofpurifiedbotulinumtypeaneurotoxintotreatexperimentaltrigeminalneuropathyinratsandpatientswithurinaryincontinenceandprostatichyperplasia AT dwifatmawatininengah applicationofpurifiedbotulinumtypeaneurotoxintotreatexperimentaltrigeminalneuropathyinratsandpatientswithurinaryincontinenceandprostatichyperplasia AT nishikawaatsushi applicationofpurifiedbotulinumtypeaneurotoxintotreatexperimentaltrigeminalneuropathyinratsandpatientswithurinaryincontinenceandprostatichyperplasia AT ohyamatohru applicationofpurifiedbotulinumtypeaneurotoxintotreatexperimentaltrigeminalneuropathyinratsandpatientswithurinaryincontinenceandprostatichyperplasia AT watanabetoshihiro applicationofpurifiedbotulinumtypeaneurotoxintotreatexperimentaltrigeminalneuropathyinratsandpatientswithurinaryincontinenceandprostatichyperplasia AT kubokitakuo applicationofpurifiedbotulinumtypeaneurotoxintotreatexperimentaltrigeminalneuropathyinratsandpatientswithurinaryincontinenceandprostatichyperplasia AT nagaiatsushi applicationofpurifiedbotulinumtypeaneurotoxintotreatexperimentaltrigeminalneuropathyinratsandpatientswithurinaryincontinenceandprostatichyperplasia AT ogumakeiji applicationofpurifiedbotulinumtypeaneurotoxintotreatexperimentaltrigeminalneuropathyinratsandpatientswithurinaryincontinenceandprostatichyperplasia |